- Product Details
Keywords
- (S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid
- CAS.114457-94-2
- N-(Pyrazinylcarbonyl)-L-phenylalanine
Quick Details
- ProName: (S)-3-Phenyl-2-(pyrazine-2-carboxamido...
- CasNo: 114457-94-2
- Molecular Formula: C14H13N3O3
- Application: Bortezomib intermediate
- DeliveryTime: 3-15 days after confirmed the order
- PackAge: 25kg/drum, or according the customers ...
- Port: Shanghai/ Hongkong/ Qingdao/ Zhengzhou
- ProductionCapacity: Metric Ton/Month
- Purity: 97-103%
- Storage: stored in a cool, dry and ventilated p...
- Transportation: By Air/Sea/Express
- LimitNum: 10 Gram
Superiority
Henan Wising Chem Co., Ltd is a national high-tech enterprise with a passion for selling and an emphasis on customer care.
We are committed to providing quality chemical products that help us become one of the most reputable, reliable and leading chemical products suppliers in the domestic and global markets.
We purpose to bring our value clients the best quality products, the most competitive prices, the shortest delivery and the best service.
Our customers include BASF, Bayer, Merck, AstraZeneca, Sun Pharma, MSN Laboratories, Unither Pharmaceuticals, CAHIC, Cadila Healthcare, and Abbott, Amgen in the US.
Wising Chem is a reliable distributor in domestic and global markets, we own an excellent reserch team based on Zhengzhou University, Shanghai Medical College of Fudan University and Henan University of Animal Husbandry&Economy, we focus on Pharmaceutical intermediates, API, rare chemiclas, and fine chemicals.
Details
Bortezomib intermediate. Bortezomib is a reversible inhibitor of 26S proteasome chymotrypsin-like activity in mammalian cells. Proteolysis can affect the cascade of multilevel signals in the cell, and this damage to the normal intracellular environment can lead to cell death. Inhibition of the 26S proteasome prevents hydrolysis of specific proteins. In vitro tests have proven that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor model in vivo tests have demonstrated that bortezomib can delay tumor growth, including multiple myeloma. Bortezomib can be used in the treatment of patients with multiple myeloma.